{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:32:57Z","timestamp":1740137577814,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T00:00:00Z","timestamp":1626480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-vitamin K antagonist oral anticoagulants (NOACs) are as effective and safe as warfarin for thromboembolic prevention and treatment. The efficacy of NOACs lacks evidence from large and randomized studies in patients with inherited severe thrombophilia, including protein S deficiency. Further, some concerns still exist regarding the relative efficacy of edoxaban in preventing arterial thromboembolism in patients with normal to high creatinine clearance (CrCl). We present a case of a rare complication of lead thrombus under standard-dose edoxaban in a patient with protein S deficiency and supernormal renal function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 65-year-old man experienced persistent chest tightness and a high level of D-dimer. Chest computed tomography (CT) showed a lead thrombus at the superior vena cava. He had a medical history including, paroxysmal atrial fibrillation (PAf), sick sinus syndrome after permanent pacemaker implantation, and transient ischemic attack. He received standard-dose edoxaban (60\u2009mg daily) after PAf was diagnosed. His estimated CrCl was 98.6\u2013102.1\u2009mL\/min. However, protein S deficiency (22.8%; normal range: 55\u2013130%) was diagnosed. After switching to dabigatran (150\u2009mg twice daily) for 3 months, the chest CT showed lead thrombus resolution and no symptoms were seen during the follow-up period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case was a rare complication of lead thrombus in a protein S deficient patient with normal renal function receiving standard-dose edoxaban. Edoxaban efficacy is uncertain in patients with protein S deficiency, and intracardiac devices also increase the risk of thromboembolic events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12959-021-00302-w","type":"journal-article","created":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T09:03:03Z","timestamp":1626512583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lead thrombus under standard-dose edoxaban in a patient with normal to high creatinine clearance and protein S deficiency"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-6134","authenticated-orcid":false,"given":"Wei-Chieh","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,17]]},"reference":[{"issue":"12","key":"302_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"10","key":"302_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"issue":"11","key":"302_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"22","key":"302_CR4","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"issue":"9","key":"302_CR5","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","volume":"46","author":"KL Wang","year":"2015","unstructured":"Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin K antagonist Oral anticoagulants for stroke prevention in Asian patients with Nonvalvular atrial fibrillation: meta-analysis. Stroke. 2015;46(9):2555\u201361. https:\/\/doi.org\/10.1161\/STROKEAHA.115.009947.","journal-title":"Stroke."},{"issue":"7","key":"302_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0091270009351883","volume":"50","author":"K Ogata","year":"2010","unstructured":"Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743\u201353. https:\/\/doi.org\/10.1177\/0091270009351883.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"302_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","volume":"134","author":"EA Bohula","year":"2016","unstructured":"Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation. 2016;134(1):24\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.022361.","journal-title":"Circulation."},{"key":"302_CR8","volume-title":"Prescribing information for Savaysa (edoxaban)","author":"US Food and Drug Administration","year":"2015","unstructured":"US Food and Drug Administration. Prescribing information for Savaysa (edoxaban). 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf. Accessed 22 Feb 2018."},{"issue":"10","key":"302_CR9","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1161\/STROKEAHA.118.021387","volume":"49","author":"HT Yu","year":"2018","unstructured":"Yu HT, Yang PS, Kim TH, Jang E, Kim D, Uhm JS, et al. Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation. Stroke. 2018;49(10):2421\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.118.021387.","journal-title":"Stroke."},{"issue":"3","key":"302_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000007018","volume":"93","author":"K Barakat","year":"2000","unstructured":"Barakat K, Robinson NM, Spurrell RA. Transvenous pacing lead-induced thrombosis: a series of cases with a review of the literature. Cardiology. 2000;93(3):142\u20138. https:\/\/doi.org\/10.1159\/000007018.","journal-title":"Cardiology."},{"issue":"4","key":"302_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s11239-018-1733-z","volume":"46","author":"A Di Vincenzo","year":"2018","unstructured":"Di Vincenzo A, Rizzo A, Russo L, Mioni R. Pacemaker-associated thrombosis in ongoing therapy with edoxaban tosylate. J Thromb Thrombolysis. 2018;46(4):549\u201350. https:\/\/doi.org\/10.1007\/s11239-018-1733-z.","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"302_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.5603\/KP.2014.0173","volume":"72","author":"P Micha\u0142ek","year":"2014","unstructured":"Micha\u0142ek P, Kubaszek-Kornatowska A, Pr\u0119gowska-Chwa\u0142a B. P\u00f3\u017ana zakrzepica \u017cy\u0142y podobojczykowej lewej po wszczepieniu uk\u0142adu stymuluj\u0105cego skutecznie leczona riwaroksabanem [Late pacemaker lead thrombosis treated with rivaroxaban]. Kardiol Pol. 2014;72(9):840. https:\/\/doi.org\/10.5603\/KP.2014.0173.","journal-title":"Kardiol Pol"},{"issue":"4","key":"302_CR13","first-page":"183","volume":"14","author":"A Adar","year":"2019","unstructured":"Adar A, \u00d6nalan O, Cakan F. Development of pacemaker Lead thrombosis in a patient with atrial fibrillation during Apixaban treatment. J Tehran Heart Cent. 2019;14(4):183\u20136.","journal-title":"J Tehran Heart Cent"},{"issue":"3","key":"302_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T van der Hulle","year":"2014","unstructured":"van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320\u20138. https:\/\/doi.org\/10.1111\/jth.12485.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"302_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/10408360600552678","volume":"43","author":"M Franchini","year":"2006","unstructured":"Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G. Inherited thrombophilia. Crit Rev Clin Lab Sci. 2006;43(3):249\u201390. https:\/\/doi.org\/10.1080\/10408360600552678.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"6","key":"302_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/MBC.0000000000000613","volume":"28","author":"A Undas","year":"2017","unstructured":"Undas A, Goralczyk T. Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients. Blood Coagul Fibrinolysis. 2017;28(6):438\u201342. https:\/\/doi.org\/10.1097\/MBC.0000000000000613.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"302_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jth.14398","volume":"17","author":"MAT Elsebaie","year":"2019","unstructured":"Elsebaie MAT, van Es N, Langston A, B\u00fcller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost. 2019;17(4):645\u201356. https:\/\/doi.org\/10.1111\/jth.14398.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"302_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","volume":"2","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory monitoring of non-vitamin K antagonist Oral anticoagulant use in patients with atrial fibrillation: a review. JAMA Cardiol. 2017;2(5):566\u201374. https:\/\/doi.org\/10.1001\/jamacardio.2017.0364.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"302_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11239-018-1643-0","volume":"45","author":"A Rottenstreich","year":"2018","unstructured":"Rottenstreich A, Zacks N, Kleinstern G, Raccah BH, Roth B, Da'as N, et al. Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis. 2018;45(4):543\u20139. https:\/\/doi.org\/10.1007\/s11239-018-1643-0.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"302_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1161\/CIRCULATIONAHA.116.022307","volume":"134","author":"JI Weitz","year":"2016","unstructured":"Weitz JI, Eikelboom JW. Urgent need to measure effects of direct Oral anticoagulants. Circulation. 2016;134(3):186\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.022307.","journal-title":"Circulation."},{"issue":"5","key":"302_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.2450\/2017.0124-17","volume":"16","author":"A Tripodi","year":"2018","unstructured":"Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, et al. Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus. 2018;16(5):462\u201370. https:\/\/doi.org\/10.2450\/2017.0124-17.","journal-title":"Blood Transfus"},{"issue":"2","key":"302_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1373\/clinchem.2012.189704","volume":"59","author":"A Tripodi","year":"2013","unstructured":"Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem. 2013;59(2):353\u201362. https:\/\/doi.org\/10.1373\/clinchem.2012.189704.","journal-title":"Clin Chem"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00302-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-021-00302-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00302-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T09:05:32Z","timestamp":1626512732000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-021-00302-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,17]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["302"],"URL":"https:\/\/doi.org\/10.1186\/s12959-021-00302-w","relation":{},"ISSN":["1477-9560"],"issn-type":[{"type":"electronic","value":"1477-9560"}],"subject":[],"published":{"date-parts":[[2021,7,17]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report followed the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964 and later revisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved this manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}